Skip to main content
. 2012 Feb 27;2012:247973. doi: 10.1155/2012/247973

Figure 1.

Figure 1

Clinical features (age, sex) of CHC patients. (a) patients who developed anti-TPO antibodies (n = 10) at six months after the start of peg-interferon and ribavirin therapy. (b) Patients who not developed anti-TPO antibodies (n = 40) at six months after the start of peg-interferon and ribavirin therapy. *P < 0.05 was statistically significant.